[8-K] Edwards Lifesciences Corp Reports Material Event

Rhea-AI Filing Summary

Edwards Lifesciences announced a planned leadership change as Chief Financial Officer Scott Ullem informed the company he will transition from his role by mid-year 2026.

The company has begun a selection process to appoint a new CFO. A press release announcing the transition plan was issued on October 30, 2025 and furnished under Item 7.01; it is not deemed “filed” under the Exchange Act.

Insights

Corporate governance analyst

Orderly CFO transition with succession search underway; neutral impact.

Edwards Lifesciences disclosed that CFO Scott Ullem plans to transition by mid-year 2026. The company has initiated a process to appoint a new CFO, indicating a structured succession approach rather than an abrupt change.

The announcement came via a press release on October 30, 2025, furnished under Item 7.01. Market impact typically hinges on continuity and the eventual appointee’s track record; the filing provides no further financial or strategic changes tied to this transition.

Key watchpoint is the identification of the successor and any stated priorities when appointed. Subsequent filings may provide specifics on timing and responsibilities.

Edwards Lifesciences Corp false 0001099800 0001099800 2025-10-30 2025-10-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 30, 2025

EDWARDS LIFESCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

Delaware		1-15525		36-4316614
(State or other jurisdiction of incorporation)		(Commission file number)		(IRS Employer Identification No.)

One Edwards Way

Irvine, California 92614

(Address of principal executive offices and zip code)

(949) 250-2500

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $1.00 per share		EW		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 30, 2025, Scott Ullem, the Chief Financial Officer of Edwards Lifesciences Corporation, a Delaware corporation (the “Corporation”), informed the Corporation of his decision to transition from his role by mid-year 2026. On October 30, 2025, the Corporation issued a press release announcing his decision. The Corporation is initiating a selection process to appoint a new Chief Financial Officer.

Item 7.01. Regulation FD Disclosure.

On October 30, 2025, the Corporation issued a press release announcing a CFO transition plan. A copy of the press release is filed as Exhibit 99.1, and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1		Press Release, issued on October 30, 2025, announcing CFO transition plan.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				EDWARDS LIFESCIENCES CORPORATION
				By:		/s/ Mark D. Peterson
						Mark D. Peterson
Date: October 30, 2025						CVP, General Counsel

3

FAQ

What did Edwards Lifesciences (EW) announce regarding its CFO?

The company announced that CFO Scott Ullem plans to transition from his role by mid-year 2026.

Is Edwards Lifesciences (EW) starting a search for a new CFO?

Yes. The company stated it is initiating a selection process to appoint a new Chief Financial Officer.

When was the CFO transition announcement made by EW?

A press release was issued on October 30, 2025 announcing the CFO transition plan.

How was the announcement furnished by Edwards Lifesciences (EW)?

It was furnished under Item 7.01 and is not deemed “filed” under the Exchange Act.

Who is the current CFO of Edwards Lifesciences (EW)?

The filing identifies Scott Ullem as the current Chief Financial Officer.

Does the filing mention changes to EW’s financial guidance or strategy?

No. The disclosure focuses on the CFO transition plan and the search process.